Tirzepatide & HFpEF: BMI, Gains & Weight Loss
Tirzepatide Shows broad Cardiovascular Benefits in Heart Failure with Preserved ejection Fraction, Especially in Patients with Higher Obesity Metrics
Table of Contents
New research presented at the American College of Cardiology (ACC) Scientific Session 2025 and published in the Journal of the American College of Cardiology highlights the notable cardiovascular benefits of tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF), especially those with higher levels of obesity. The study, led by Barry A. Borlaug, MD, of Mayo Clinic, suggests that excess body fat, especially visceral fat, plays a crucial role in driving HFpEF severity and that incretin therapies like tirzepatide offer a promising avenue for management.
Key Findings: obesity Phenotype and Tirzepatide Efficacy
The study categorized patients based on their body mass index (BMI) and waist-to-height ratio (WHtR), revealing distinct characteristics within different obesity strata.
Highest BMI Tertile: patients in the highest BMI tertile were younger, predominantly women, and exhibited more severe heart failure, greater volume overload, and heightened inflammation.
Higher whtr: individuals with a higher waist-to-height ratio mirrored these patterns, additionally demonstrating shorter 6-minute walk distances and more severe kidney disease.
Crucially, the use of tirzepatide, compared to placebo, consistently reduced the risk of cardiovascular death or worsening heart failure across all BMI ranges and waist-to-height ratios. This indicates a broad efficacy of the drug regardless of the degree of obesity.
Tirzepatide’s Impact on Functional Capacity and Biomarkers
The research further detailed tirzepatide’s impact on functional capacity and key health markers:
6-Minute Walk Distance: Tirzepatide was associated with greater improvements in the 6-minute walk distance in patients within the highest BMI range (37.5 m) compared to those in the middle (26.3 m) and lower (9.9 m) ranges. A statistically significant trend (P = .025) supported these findings. These findings underscore the critical role of excess body fat in the obesity phenotype of HFpEF. “These data provide further evidence supporting the importance of excess body fat, particularly visceral fat, as driving HF severity in patients with the obesity phenotype of HFpEF,” the researchers reported. Experts commenting on the study emphasized the need for personalized treatment strategies. “While these findings reinforce the role of incretin therapies in HFpEF management, these data, perhaps more importantly, highlight the urgent need for precision strategies to define obesity and direct therapy to those who will benefit most,” wrote experts in an accompanying editorial.This suggests that while tirzepatide offers broad benefits,tailoring its use based on specific obesity metrics could optimize outcomes. The study,led by Barry A. Borlaug, MD, of Mayo Clinic in Rochester, Minnesota, was published online on July 21, 2025, in the
Weight Loss and Blood Pressure: Improvements in weight loss and systolic blood pressure followed a similar pattern, correlating with higher BMI ranges.
Weight Loss Correlation: After 52 weeks of tirzepatide treatment, patients who experienced greater weight loss also showed more substantial gains in their 6-minute walk distance and improvements in the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) (P < .0001 for both). Similar benefits were observed in individuals with larger reductions in waist circumference.
Expert Commentary and Clinical Implications
Study Details and limitations
Limitations of the study include:
Categorization: Classifying patients into tertiles for BMI or waist-to-height ratio might have obscured subtle trends. Generalizability: The trial included a higher proportion of women and participants from latin America, which could limit the generalizability of the findings to other populations.
Measurement Precision: Imaging-based methods could potentially offer more precise measurements of obesity compared to BMI and WHtR.
Disclosures: The original trial was funded by Eli Lilly and company. The lead author reported receiving grants from the National Heart, Lung, and Blood Institute and the US Department of Defense, as well as research grants and consulting fees from several pharmaceutical companies. They are also a named inventor for tools and approaches to treat heart failure. Several other authors reported being employees of or consultants for Eli Lilly and Company and other companies.